FLEXTRADE
21.9.2021 09:02:10 CEST | Business Wire | Press release
OpenFin, the operating system (OS) for enterprise productivity, today announced that LSEG’s (London Stock Exchange Group) Turquoise Plato is connecting to OpenFin in response to the industry need for workflow efficiencies, application interoperability, and a more unified desktop experience for the buy-side and member firm users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005467/en/
Turquoise has a proven track record in delivering innovation and liquidity opportunities to the market, with Turquoise Plato Block Discovery™ having seen record levels of block trading activity on Turquoise® and Turquoise Europe™ in 2020. With this collaboration, Turquoise is continuing to deliver on its mission to identify efficient, collaborative operating models that reduce the implicit cost of trading, contribute to long-term investment returns and drive sustainable growth.
Turquoise on OpenFin™ delivers an insightful data feed directly into trader workflows to support liquidity discovery and decision making processes leveraging OpenFin’s open architecture. The API passes FDC3 compliant Context objects, and makes use of OpenFin’s message bus to pass that data to OpenFin-enabled applications including visualisation tools, in-house and 3rd party applications.
Dr Robert Barnes, Group Head of Securities Trading & CEO of Turquoise Global Holdings, LSEG, said: “As a market operator, Turquoise is well positioned to bring the industry together around a common ambition: to collaborate, innovate and to improve efficiencies on traders’ desktops. This will not only support best execution efforts but also improve performance for end investors as it helps us reduce the slippage cost at the point of execution. We are delighted Turquoise® and Turquoise Europe™ are the first trading venues to connect to OpenFin and offer this new functionality to the buy-side.”
Adam Toms, European CEO of OpenFin, commented : “We are witnessing a continued shift towards more collaborative mindsets and platforms. With forward thinking firms such as Turquoise working with the industry to create solutions that make the financial desktop more intuitive, automated and powerful, firms can unlock the true potential of interoperability and contextual workflows on their financial desktop. Operational complexity and costs arising from bilateral integrations are fast becoming a thing of the past as users can now access the right tools and data sets, surfaced directly into their workflows, delivering powerful capabilities and tangible results.”
Toms added: “Collaboration and innovation are central to our mission to simplify app distribution, unify the digital workspace and enable seamless communication and workflows between applications. We are very excited to be working with Turquoise to bring new, visionary models of collaboration to life and to market.”
OpenFin provides a common web-based OS layer across the financial services industry to power next-generation applications and desktop experiences. OpenFin technology is deployed on 300,000 desktops across the industry, powering over 3,500 applications in more than 2,400 buy-side and sell-side firms in 60+ countries.
FlexTrade Systems will be the first to deliver the Turquoise data feed into their flagship EMS via the OpenFin message bus. Traders can then act on that data, automate processes and take advantage of emerging liquidity opportunities. Built-in visualisation capabilities ensure the block trading activity from Turquoise Plato Order Books™ is easy to digest and subsequently interact with.
Andy Mahoney, Managing Director, EMEA at FlexTrade Systems, added : “We are delighted to work with Turquoise and OpenFin to support liquidity discovery and execution opportunities, and bring tangible benefits to the buy-side trading desk. It helps our clients customise their execution workflows, perform optimally on every trade and achieve best execution without compromise.”
About OpenFin
Move Fast. Break Nothing. OpenFin is the operating system for enterprise productivity, enabling app distribution, workspace management and workflow automation. Used by 90% of global financial institutions, OpenFin deploys more than 3,500 desktop applications to more than 2,400 buy-side and sell-side firms. OpenFin investors include Bain Capital Ventures, Barclays, CME Ventures, DRW Venture Capital, HSBC, J.P. Morgan, NYCA Partners, Pivot Investment Partners, Standard Chartered and Wells Fargo Strategic Capital among others. The company is based in New York with an office in London and presence in Hong Kong.
About FlexTrade
FlexTrade Systems is a global leader in high performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world’s first broker-neutral, execution management trading system, which allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005467/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom